Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.
Although CpG oligodeoxynucleotides (CpG ODNs) are known to enhance resistance against infection in a number of animal models, little is known about the CpG-induced protection against acute fatal sepsis such as that associated with the highly virulent bacterium Burkholderia pseudomallei. We previously demonstrated in an in vitro study that immunostimulatory CpG ODN 1826 enhances phagocytosis of B. pseudomallei and induces nitric oxide synthase and nitric oxide production by mouse macrophages. In the present study, CpG ODN 1826 given intramuscularly to BALB/c mice 2 to 10 days prior to B. pseudomallei challenge conferred better than 90% protection. CpG ODN 1826 given 2 days before the bacterial challenge rapidly enhanced the innate immunity of these animals, judging from the elevated serum levels of interleukin-12 (IL-12)p70 and gamma interferon (IFN-gamma) over the baseline values. No bacteremia was detected on day 2 in 85 to 90% of the CpG-treated animals, whereas more than 80% of the untreated animals exhibited heavy bacterial loads. Although marked elevation of IFN-gamma was found consistently in the infected animals 2 days after the bacterial challenge, it was ameliorated by the CpG ODN 1826 pretreatment (P = 0.0002). Taken together, the kinetics of bacteremia and cytokine profiles presented are compatible with the possibility that protection by CpG ODN 1826 against acute fatal septicemic melioidosis in this animal model is associated with a reduction of bacterial load and interference with the potential detrimental effect of the robust production of proinflammatory cytokines associated with B. pseudomallei multiplication.
Wongratanacheewin
Surasakdi
S
Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. sura_wng@kku.ac.th
Kespichayawattana
Wannapa
W
Intachote
Pakamas
P
Pichyangkul
Sathit
S
Sermswan
Rasana W
RW
Krieg
Arthur M
AM
Sirisinha
Stitaya
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D016470:Bacteremia / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D016957:Burkholderia pseudomallei / Q000302:isolation & purification / Q000472:pathogenicity; D015169:Colony Count, Microbial; D018899:CpG Islands / Q000276:immunology; D004247:DNA / Q000008:administration & dosage* / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D008554:Melioidosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; C423449:CpG ODN 1826; D009838:Oligodeoxyribonucleotides; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D004247:DNA